Satralizumab Reduces Neuromyelitis Optica Spectrum Disorder Relapse Rate

Promising results from two phase 3 studies suggest satralizumab may reduce the frequency of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD), according to a presentation at the virtual Association for Research in Vision and Ophthalmology meeting.

Neuromyelitis optica spectrum disorder is a chronic disease of the central nervous system that presents with optic neuritis or optic myelitis.

In the presentation, Zdenka Haskova, MD, provided data from the phase 3 SAkuraSky study, which investigated the efficacy of satralizumab, a humanized monoclonal antibody thats targets the IL-6 receptor, in combination with baseline immunosuppressive therapy, and the phase 3 SAkuraStar study, which investigated satralizumab as a monotherapy.

In the studies, 178 patients were included, with 104 patients receiving satralizumab 120 mg injected subcutaneously every 4 weeks and 74 patients receiving placebo.

In monotherapy and in combination, satralizumab was found to significantly reduced the frequency of relapses, according to Dr Haskova.

The virtual presentation is available here.

Reference

Haskova Z, de Seze J, Weinshenker B, et al. Efficacy and safety of satralizumab from two phase 3 trials in neuromyelitis optica spectrum disorder. Presented at: Association for Research in Vision and Ophthalmology annual meeting.